RARE DISEASE
Thymic epithelial neoplasm
Thymic epithelial neoplasm
Thymic epithelial neoplasm
Synonyms: TEN, Thymic epithelial tumor
Synonyms: TEN, Thymic epithelial tumor
Synonyms: TEN, Thymic epithelial tumor
Drug discovery
4
drugs
With orphan designations
Overview
Thymic epithelial neoplasms (TENs) are rare malignancies originating from thymic epithelium, encompassing thymoma (most common), thymic carcinoma, and thymic neuroendocrine tumors. These tumors primarily arise in the anterior mediastinum and exhibit variable aggressiveness, with thymic carcinomas being the most aggressive. Clinical presentations range from asymptomatic incidental findings to paraneoplastic syndromes like myasthenia gravis (30-50% of thymomas). Diagnosis involves histopathology (WHO classification) and staging (Masaoka-Koga system), guiding multimodal therapy [1][4][7][12].
Population
Therapies
Resectable tumors: Complete thymectomy ± adjuvant radiotherapy (45–60 Gy), with VATS for early-stage lesions [3][5][20].
Unresectable/localized disease: Neoadjuvant platinum-based chemotherapy (CAP/carboplatin-paclitaxel) followed by surgery/radiotherapy [3][8][14].
Advanced/metastatic disease: Platinum-etoposide or anthracycline regimens; emerging therapies include sunitinib (VEGFR/PDGFR inhibitor) and PD-1 inhibitors (limited by autoimmune toxicity) [8][14][20].
Categories: rare neoplastic diseases
Research Papers
962 drug discovery papers about Thymic epithelial neoplasm, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
962 drug discovery papers about Thymic epithelial neoplasm, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-16 | Is phrenic nerve-sparing worthwhile for phrenic-involved thymic epithelial tumors? A retrospective cohort study.
To determine whether phrenic nerve (PN) sparing offers a worthwhile trade-off between functional preservation and oncologic safety compared with resection in PN-involved thymic epithelial tumors (TETs), and to establish an objective tool for postoperative respiratory risk stratification. In this retrospective cohort of patients with TETs with PN invasion, 122 propensity score-matched cases were analyzed from 2016 to 2024. PN preservation or resection was determined intraoperatively based on the extent of invasion. The diaphragmatic elevation (DE) ratio was calculated as [(preoperative diaphragm-apex distance - postoperative distance)/preoperative distance] × 100% according to X-rays, and cutoff values were defined by respiratory complication risk. Perioperative and oncologic outcomes were compared between the PN-sparing and PN resection groups. Overall perioperative morbidity and recovery outcomes were comparable between the PN-sparing and PN-resection groups; however, tumor progression was significantly more frequent on the PN-sparing group (39.3% vs 23.0%), resulting in worse progression-free survival (PFS) (P = .027), although overall survival (OS) remained comparable in the 2 groups. Multivariable analysis identified PN preservation as an independent predictor of progression (P = .049). Furthermore, our receiver operating characteristic-derived DE classification scheme (mild, ≤15%; moderate, 15-25%; severe, ≥25%) predicted severe postoperative respiratory complications (P < .001). PN resection improves PFS without increasing severe perioperative complications, although OS is comparable to that with PN-sparing.
2026-07-21 | Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026—A Narrative Review
Palliative systemic therapy for advanced thymic epithelial tumors (TET) is challenging due to scarce evidence and biological heterogeneity. Scientific discussion, as in this review, is limited to cross-trial comparisons of small, non-randomized studies. Platinum-based combination chemotherapy is the standard first-line treatment. Here, we challenge the addition of anthracyclines to platinum in thymoma. We critically appraise new combinations with antiangiogenic drugs and immune checkpoint inhibitors (ICI) in thymic carcinoma and their implications for therapy sequences. We review the data on classic genomics-based targeted therapy that does not benefit most patients and explore established and upcoming biomarkers including KIT and HER2. Finally, we discuss investigational therapies like anti-TROP2 antibody-drug conjugates and proteasome inhibitors, as well as topics and design of future research.
2026-07-11 | Identification of CCL4-positive macrophages and their associated immune microenvironment in thymic epithelial tumors
Thymic epithelial tumors (TETs) are one of the primary tumor types in the mediastinum, originating from thymic epithelial cells. Recent studies have highlighted the close association between specific macrophage subpopulations and the tumor immunosuppressive microenvironment. However, the characteristics and immunological functions of macrophages within TETs are still poorly understood. Single-cell transcriptome sequencing and the TCGA-THYM data were collected for integrated analysis of macrophage characteristics. The target cells were verified using multiplex immunofluorescence (mIF) staining. Functional validation was performed using Western blot and Transwell migration assays. Drug sensitivity was evaluated by predicting the half-maximal inhibitory concentration through oncoPredict. A group of CCL4 + macrophage subpopulations was clustered from the TETs myeloid single-cell subpopulation. By cell communication analysis, CCL4 + macrophages were positively correlated with exhausted T cells and regulatory T cells (Tregs). mIF staining confirmed a significant positive association between CCL4 + CD163 + cells and FOXP3 + CD4 + cells in terms of their proportions (r = 0.679, p < 0.001). Furthermore, in vitro experiments demonstrated that macrophages promoted Treg migration, which was significantly reduced by CCL4 blockade ( p < 0.05). Additionally, there are significant differences in drug sensitivity predictions and survival between TET patients with high and low CCL4 expression. These findings suggest that CCL4 + macrophages are specifically present in TETs and are related to the immune microenvironment of Treg infiltration.The expression of CCL4 in other immune cell subpopulations and cohorts still needs further verification to clarify its unique role in TET macrophages.
2026-07-10 | Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.
Thymic epithelial tumours (TETs), including thymomas and thymic carcinomas, are relatively rare anterior mediastinal malignancies. Thymomas are well known to be associated with various autoimmune diseases, such as myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. The mainstay of treatment for all TETs is complete surgical resection, although recent advances in irradiation and anti-tumour drug therapies are increasingly indicated for advanced or recurrent disease. The pathobiology of TETs was reviewed to consider optimal treatment strategies based on their immuno-oncological characteristics. A comprehensive literature search was conducted using PubMed, focusing on the biology and treatment of TETs, along with integration of our original research data. Pathobiology is different between thymoma and thymic carcinoma. Incomplete T cell development is observed in thymoma, which may affect patient autoimmunity. Type AB, B1, and B2 thymomas harbour abundant immature T cells, which cannot act as effector T cells in treatment using immune checkpoint inhibitors (ICIs). Neoplastic thymic epithelial cells (TECs) express programmed cell death-ligand 1 (PD-L1) at varying levels, and frequent genetic aberrations are observed according to the World Health Organization (WHO) classification. Germinal centre formation in the surrounding thymus may have a clinical role in thymoma-associated MG. Regarding treatment strategies, radical minimally invasive thymectomy using robotic technology is now available for MG. Effective molecular-targeted and ICI therapies have recently been introduced, and further novel targeted therapies are currently under development. WHO histological subtypes and inflammatory biomarkers are practically useful for determining the treatment strategy. A fundamental understanding of pathobiology and immuno-oncology is crucial for the appropriate management of TETs.
2026-07-10 | Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.
Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare tumors. Although systemic therapy is commonly used for unresectable advanced or recurrent TETs, establishing robust evidence remains challenging. This narrative review summarizes current evidence and incorporates the latest clinical trial data, reporting outcomes separately for thymoma and thymic carcinoma whenever possible. We also highlight practical considerations relevant to clinical practice, including dosing strategies and toxicity management. We searched PubMed and Google Scholar for prospective and retrospective original studies, meta-analyses, review articles, and case studies published up to November 2025 using terms including "thymoma", "thymic carcinoma", "thymic cancer", "thymic tumors", "thymic epithelial tumors", "chemotherapy", "systemic treatment", "immunotherapy", and "targeted therapy". Ongoing trials were identified via ClinicalTrials.gov and the Japan Registry of Clinical Trials. Retrospective studies enrolling fewer than 15 participants were excluded. Systemic therapy for advanced TETs continues to include cytotoxic chemotherapy as a major component. In selected settings, particularly in thymic carcinoma, targeted therapy and immune checkpoint inhibitors (ICIs) represent additional active options. Emerging trials suggest that combination strategies may enhance efficacy. Novel drugs, including bispecific antibodies and antibody-drug conjugates, are being evaluated in ongoing phase II trials. Despite the rarity of TETs, systemic treatment options have gradually expanded through the accumulation of evidence from small phase II studies. Future advances will require collaborative prospective trials to validate predictive biomarkers and support biomarker-enriched trial designs.
2026-08-16 | Is phrenic nerve-sparing worthwhile for phrenic-involved thymic epithelial tumors? A retrospective cohort study.
To determine whether phrenic nerve (PN) sparing offers a worthwhile trade-off between functional preservation and oncologic safety compared with resection in PN-involved thymic epithelial tumors (TETs), and to establish an objective tool for postoperative respiratory risk stratification. In this retrospective cohort of patients with TETs with PN invasion, 122 propensity score-matched cases were analyzed from 2016 to 2024. PN preservation or resection was determined intraoperatively based on the extent of invasion. The diaphragmatic elevation (DE) ratio was calculated as [(preoperative diaphragm-apex distance - postoperative distance)/preoperative distance] × 100% according to X-rays, and cutoff values were defined by respiratory complication risk. Perioperative and oncologic outcomes were compared between the PN-sparing and PN resection groups. Overall perioperative morbidity and recovery outcomes were comparable between the PN-sparing and PN-resection groups; however, tumor progression was significantly more frequent on the PN-sparing group (39.3% vs 23.0%), resulting in worse progression-free survival (PFS) (P = .027), although overall survival (OS) remained comparable in the 2 groups. Multivariable analysis identified PN preservation as an independent predictor of progression (P = .049). Furthermore, our receiver operating characteristic-derived DE classification scheme (mild, ≤15%; moderate, 15-25%; severe, ≥25%) predicted severe postoperative respiratory complications (P < .001). PN resection improves PFS without increasing severe perioperative complications, although OS is comparable to that with PN-sparing.
2026-07-21 | Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026—A Narrative Review
Palliative systemic therapy for advanced thymic epithelial tumors (TET) is challenging due to scarce evidence and biological heterogeneity. Scientific discussion, as in this review, is limited to cross-trial comparisons of small, non-randomized studies. Platinum-based combination chemotherapy is the standard first-line treatment. Here, we challenge the addition of anthracyclines to platinum in thymoma. We critically appraise new combinations with antiangiogenic drugs and immune checkpoint inhibitors (ICI) in thymic carcinoma and their implications for therapy sequences. We review the data on classic genomics-based targeted therapy that does not benefit most patients and explore established and upcoming biomarkers including KIT and HER2. Finally, we discuss investigational therapies like anti-TROP2 antibody-drug conjugates and proteasome inhibitors, as well as topics and design of future research.
2026-07-11 | Identification of CCL4-positive macrophages and their associated immune microenvironment in thymic epithelial tumors
Thymic epithelial tumors (TETs) are one of the primary tumor types in the mediastinum, originating from thymic epithelial cells. Recent studies have highlighted the close association between specific macrophage subpopulations and the tumor immunosuppressive microenvironment. However, the characteristics and immunological functions of macrophages within TETs are still poorly understood. Single-cell transcriptome sequencing and the TCGA-THYM data were collected for integrated analysis of macrophage characteristics. The target cells were verified using multiplex immunofluorescence (mIF) staining. Functional validation was performed using Western blot and Transwell migration assays. Drug sensitivity was evaluated by predicting the half-maximal inhibitory concentration through oncoPredict. A group of CCL4 + macrophage subpopulations was clustered from the TETs myeloid single-cell subpopulation. By cell communication analysis, CCL4 + macrophages were positively correlated with exhausted T cells and regulatory T cells (Tregs). mIF staining confirmed a significant positive association between CCL4 + CD163 + cells and FOXP3 + CD4 + cells in terms of their proportions (r = 0.679, p < 0.001). Furthermore, in vitro experiments demonstrated that macrophages promoted Treg migration, which was significantly reduced by CCL4 blockade ( p < 0.05). Additionally, there are significant differences in drug sensitivity predictions and survival between TET patients with high and low CCL4 expression. These findings suggest that CCL4 + macrophages are specifically present in TETs and are related to the immune microenvironment of Treg infiltration.The expression of CCL4 in other immune cell subpopulations and cohorts still needs further verification to clarify its unique role in TET macrophages.
2026-07-10 | Pathobiology of thymic epithelial tumours and the treatment strategy based on immuno-oncological characteristics: a narrative review.
Thymic epithelial tumours (TETs), including thymomas and thymic carcinomas, are relatively rare anterior mediastinal malignancies. Thymomas are well known to be associated with various autoimmune diseases, such as myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. The mainstay of treatment for all TETs is complete surgical resection, although recent advances in irradiation and anti-tumour drug therapies are increasingly indicated for advanced or recurrent disease. The pathobiology of TETs was reviewed to consider optimal treatment strategies based on their immuno-oncological characteristics. A comprehensive literature search was conducted using PubMed, focusing on the biology and treatment of TETs, along with integration of our original research data. Pathobiology is different between thymoma and thymic carcinoma. Incomplete T cell development is observed in thymoma, which may affect patient autoimmunity. Type AB, B1, and B2 thymomas harbour abundant immature T cells, which cannot act as effector T cells in treatment using immune checkpoint inhibitors (ICIs). Neoplastic thymic epithelial cells (TECs) express programmed cell death-ligand 1 (PD-L1) at varying levels, and frequent genetic aberrations are observed according to the World Health Organization (WHO) classification. Germinal centre formation in the surrounding thymus may have a clinical role in thymoma-associated MG. Regarding treatment strategies, radical minimally invasive thymectomy using robotic technology is now available for MG. Effective molecular-targeted and ICI therapies have recently been introduced, and further novel targeted therapies are currently under development. WHO histological subtypes and inflammatory biomarkers are practically useful for determining the treatment strategy. A fundamental understanding of pathobiology and immuno-oncology is crucial for the appropriate management of TETs.
2026-07-10 | Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.
Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare tumors. Although systemic therapy is commonly used for unresectable advanced or recurrent TETs, establishing robust evidence remains challenging. This narrative review summarizes current evidence and incorporates the latest clinical trial data, reporting outcomes separately for thymoma and thymic carcinoma whenever possible. We also highlight practical considerations relevant to clinical practice, including dosing strategies and toxicity management. We searched PubMed and Google Scholar for prospective and retrospective original studies, meta-analyses, review articles, and case studies published up to November 2025 using terms including "thymoma", "thymic carcinoma", "thymic cancer", "thymic tumors", "thymic epithelial tumors", "chemotherapy", "systemic treatment", "immunotherapy", and "targeted therapy". Ongoing trials were identified via ClinicalTrials.gov and the Japan Registry of Clinical Trials. Retrospective studies enrolling fewer than 15 participants were excluded. Systemic therapy for advanced TETs continues to include cytotoxic chemotherapy as a major component. In selected settings, particularly in thymic carcinoma, targeted therapy and immune checkpoint inhibitors (ICIs) represent additional active options. Emerging trials suggest that combination strategies may enhance efficacy. Novel drugs, including bispecific antibodies and antibody-drug conjugates, are being evaluated in ongoing phase II trials. Despite the rarity of TETs, systemic treatment options have gradually expanded through the accumulation of evidence from small phase II studies. Future advances will require collaborative prospective trials to validate predictive biomarkers and support biomarker-enriched trial designs.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Thymic epithelial neoplasm.
4 orphan drug designations for Thymic epithelial neoplasm.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
recombinant fully human IgG1 anti-PDL1 monoclonal antibody conjugated to a DNA topoisomerase I inhibitor | antibodies | FDA | 2025-10-16 | — | Shanghai Henlius Biotech, Inc. |
anti-human programmed cell death protein 1 linked to a human IgG4Fc and a human no-a-IL-2 mutein | antibodies | FDA | 2025-08-27 | — | Anwita Biosciences, Inc. |
humanized bispecific IgG1 antibody that can simultaneously bind to both programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4 | antibodies | FDA | 2020-09-02 | — | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
milciclib maleate | small molecules | FDA | 2012-09-20 | — | Tiziana Life Sciences PLC |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.